Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration

What Was Tested

This randomized controlled trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.

Although GHRH(1-29)-NH2 was rapidly eliminated after intravenous injection, GH levels were elevated for about 3 hours.

Who Took Part

According to the abstract, 30 men were involved.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The men were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the men and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

What Was Measured

Although GHRH(1-29)-NH2 was rapidly eliminated after intravenous injection, GH levels were elevated for about 3 hours.

The subject headings attached to it are Biological Availability, Circadian Rhythm, Growth Hormone and Sermorelin.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 30 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Acta paediatrica (Oslo, Norway : 1992). Supplement), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.